Merck KGaA
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. Covers the Healthcare business sector of Merck KGaA, Darmstadt, Germany only. The Life Science business sector, which sells lab tools and software, is out of scope except where Healthcare is the user, and no Merck & Co. (MSD) material is used.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 6 | 4 | live | 1 | 3 |
| Research labs and data | 3 | 3 | build underway | 0 | 1 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Merck KGaA scores 6 out of 10 for priority and 4 out of 10 for delivery in AI in drug discovery. Healthcare uses AIDDISON, the group's generative AI discovery platform, internally in early discovery, alongside a Predictive Modeling Platform for molecule design and RDKit for molecular design data, with no adoption metric published. Research labs and data scores 3 for priority and 3 for delivery: the company says it is still building an automated design-make-test-analyse platform powered by lab automation and AIDDISON. In the last 12 months one AI discovery commitment was made public, a group high-performance computer in Munich built with Lenovo and Equinix and now operating, against one the year before, an imec co-development of microphysiological systems; none was made public for research labs and data in either year. On 6 October 2026 Healthcare had 3 AI in drug discovery roles open and 1 research labs and data role, a synthetic and discovery chemistry post that counts under both themes.
AI in drug discovery
What the company says: Priority 6
we also use it internally in our Healthcare business sector in early stages of drug discovery. Our AI in drug discovery program will accelerate the discovery of new and better drug candidates
2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41
successfully launch a state-of-the-art high-performance computer in Munich, Germany, designed to accelerate innovation across the three business sectors ... streamline drug discovery processes in its Healthcare business sector
one-HPC: High-performance computer launched with Lenovo and Equinix, 20 Nov 2025
RDKit helps our research and development scientists within our Healthcare business sector ... said Arvind Rajpal, Head of Discovery & Development Technologies at Research and Development within the Healthcare business sector of Merck KGaA, Darmstadt, Germany
RDKit conference with more than 300 participants (news release), 21 Sep 2026
What it shows running: Delivery 4, live
AIDDISON™, our generative AI-powered active ingredient discovery platform. In addition to external commercialization, we also use it internally in our Healthcare business sector in early stages of drug discovery.
2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41
Predictive Modeling Platform , a tool for AI-driven design of drug-like molecules for the Healthcare business sector, recently recognized with an in-house award
RDKit conference with more than 300 participants (news release), 21 Sep 2026
RDKit helps our research and development scientists within our Healthcare business sector turn chemical data into AI-ready representations and actionable insights for faster, better-informed molecular design.
RDKit conference with more than 300 participants (news release), 21 Sep 2026
has collaborated with Lenovo Group Ltd., Hongkong, and Equinix Inc., Redwood City, USA, to successfully launch a state-of-the-art high-performance computer in Munich, Germany
one-HPC: High-performance computer launched with Lenovo and Equinix, 20 Nov 2025
Our new high-performance computer enhances our research by significantly reducing time and cost.
one-HPC: High-performance computer launched with Lenovo and Equinix, 20 Nov 2025
Commitments made public in the last 12 months: 1
- Group high-performance computer (Lenovo, Equinix): Group HPC launched in Munich for three sectors; release names Healthcare drug discovery and AI and machine-learning workloads. New, operational, 20 Nov 2025. Published by: company.
Commitments made public in the year before: 1
- imec microphysiological systems (MPS) co-development: Co-development of sensor-equipped MPS platform to generate AI training data for drug discovery; to be validated in Healthcare labs. New, announced, 20 May 2025. Published by: joint release.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 3
- Senior Scientist - Oligo Bioinformatics, Billerica, Massachusetts, United States
- Principal Scientist, Synthetic & Discovery Chemistry, Billerica, Massachusetts, United States
- Principal Scientist, Translational Quantitative Pharmacology, Billerica, Massachusetts, United States
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
What the company says: Priority 3
We are continuing to build our automated design-make-test-analyze platform powered by lab automation and AIDDISON
2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41
What it shows running: Delivery 3, build underway
We are continuing to build our automated design-make-test-analyze platform powered by lab automation and AIDDISON
2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 1
- Principal Scientist, Synthetic & Discovery Chemistry, Billerica, Massachusetts, United States
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Two questions to investigate (Ortent's interpretation)
- Who decides on ELN and data systems for the automated discovery lab, when discovery AI and automation sit across the AIDD unit's Boston-area lab, Healthcare R&D's Discovery and Development Technologies function, the group Science and Technology Office and Life Science products such as AIDDISON?
- Who holds the budget for discovery compute and AI tools used by Healthcare R&D: the Healthcare sector, the Chief Science and Technology Officer's office or Digital Enterprise Solutions, and how is the cost of shared assets such as the group high-performance computer charged to Healthcare?
Coverage limits
merckgroup.com redirects to the US and Canada site emdgroup.com, where the global newsroom archive returned errors, so releases published only on the global site, including German-only releases, may be missing. Call transcripts were not found and not every quarterly report was read, so newsroom, results and partner newswire searches are partial in both years. Business Wire, GlobeNewswire, Fierce Biotech and several other sites blocked access, and a date check on the high-performance computer launch did not run, which could move it between years. The scores rest on the documents that could be read, and missing ones could hold further evidence.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call